To date, over 137 million controlled dangerous substance, human growth hormone and gabapentin prescriptions have been entered into the NJPMP from more than 3,300 New Jersey licensed pharmacies. Since the NJPMP began operating in 2011, a total of 53,259 prescribers and 8,137 pharmacists have registered for access to the NJPMP, representing approximately 97 percent of eligible prescribers. The monitoring program allows healthcare professionals to see a patient’s prescription drug history with the aim of improving overall prescribing practices and reducing the risk of potential abuse or fraud by patients who obtain prescriptions from multiple providers. The NJPMP, within the Division of Consumer Affairs (the “Division”), is an electronic database that collects information from pharmacies on the dispensing of controlled dangerous substances, like opioids, to individual patients. EHR integration improves ease of access and increases utilization of the NJPMP so that healthcare providers can make the best data-informed treatment decisions for their patients. Those funds will be used to support the NJPMP’s Electronic Health Record (EHR) integration. This is in addition to the $972,426 in opioid settlement funds provided by Governor Murphy for the NJPMP. Levy, Acting Director, Office of the New Jersey Coordinator for Addiction Response and Enforcement Strategies (NJCARES), today announced that the New Jersey Prescription Monitoring Program (“NJPMP”) was awarded $1.4 million in competitive federal funding from the FY22 Harold Rogers Prescription Drug Monitoring Program to enhance the State’s existing program that helps prescribers monitor patient use of opioid painkillers and other controlled drugs that can lead to addiction and fatal overdoses.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |